Agomab Therapeutics NV
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
State of Incorporation Belgium
Country Belgium
Business Address POSTHOFLEI 1/6, ANTWERPEN, , 2600
Mailing Address POSTHOFLEI 1/6, ANTWERPEN, , 2600
Phone 32 3 302 35 30
Fiscal Year End 1231
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 9, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | February 6, 2026 | View on SEC |
| F-1/A Foreign IPO registration amendment | January 29, 2026 | View on SEC |
| F-1 Foreign company IPO registration | January 16, 2026 | View on SEC |
IPO Filings
F-1 January 16, 2026
- Clear therapeutic focus, lead drug candidate, and pipeline assets.
- Notable development milestone achieved.
Related Companies
Companies in the same industry (SIC: 2836)
AMGEN INC
AMGN Biological Products, (No Diagnostic Substances)
INTENSITY THERAPEUTICS, INC.
INTS Biological Products, (No Diagnostic Substances)
Vitro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
Surrozen, Inc./DE
SRZN Biological Products, (No Diagnostic Substances)
Twist Bioscience Corp
TWST Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.